Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors

被引:11
作者
Ikuta, Kunihiro [1 ]
Urakawa, Hiroshi [1 ]
Kozawa, Eiji [1 ]
Arai, Eisuke [1 ]
Zhuo, Lisheng [2 ]
Futamura, Naohisa [1 ]
Hamada, Shunsuke [1 ]
Kimata, Koji [2 ]
Ishiguro, Naoki [1 ]
Nishida, Yoshihiro [1 ]
机构
[1] Nagoya Univ, Dept Orthopaed Surg, Grad Sch & Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Aichi Med Univ, Nagakute, Aichi 48011, Japan
关键词
Malignant peripheral nerve sheath tumors; Hyaluronan; Neurofibroma; Prognostic factor; SYNTHASE EXPRESSION; OVARIAN-CANCER; CELLS; RETENTION; SURVIVAL; INSTITUTION; INHIBITION; CARCINOMA; PROMOTES; GROWTH;
D O I
10.1007/s10585-014-9662-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hyaluronan (HA) regulates malignant tumor growth, invasion, and metastasis. However, few studies have focused on the roles of HA in tumorigenicity in malignant peripheral nerve sheath tumors (MPNST). In this study, we sought to clarify the prognostic value of HA in patients with MPNST. Specimens obtained from 15 patients with neurofibroma and 30 with MPNST were subjected to HA staining and scored as three grades. Protein expressions of HA synthase 1-3 were examined in the 22 MPNST tissue samples available. Statistically higher HA positivity was observed in MPNST as compared with neurofibroma (P = 0.020). The univariate analysis revealed that increased HA expression, age, neurofibromatosis type 1 (NF1) status, large tumor size, and histological grade were significantly associated with reduced overall survival of patients with MPNST; while increased HA expression, NF1 status, tumor size, and histological grade were correlated with disease-free survival. However, HA synthase 1-3 expression related to neither overall survival nor disease-free survival of these patients. In multivariate analysis, large tumor size (P = 0.022) was an independent prognostic factor for overall survival, and HA expression (P = 0.028) and tumor size (P = 0.002) were independent prognostic factors for disease-free survival. Statistically higher levels of HA in the human MPNST cells were observed compared with neurofibroma cells in vitro. Our results demonstrate that HA expression can be a useful marker in differentiating MPNST from neurofibroma, and in identifying patients with a poor prognosis. Hyaluronan-targeting therapy for patients with MPNST may have potential as a therapeutic tool.
引用
收藏
页码:715 / 725
页数:11
相关论文
共 44 条
[1]   Malignant peripheral nerve sheath tumors - Prognostic factors and survival in a series of patients treated at a single institution [J].
Anghileri, Matteo ;
Miceli, Rosalba ;
Fiore, Marco ;
Mariani, Luigi ;
Ferrari, Andrea ;
Mussi, Chiara ;
Lozza, Laura ;
Collini, Paola ;
Olmi, Patrizia ;
Casali, Paolo G. ;
Pilotti, Silvana ;
Gronchi, Alessandro .
CANCER, 2006, 107 (05) :1065-1074
[2]  
Anttila MA, 2000, CANCER RES, V60, P150
[3]   Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo [J].
Arai, E. ;
Nishida, Y. ;
Wasa, J. ;
Urakawa, H. ;
Zhuo, L. ;
Kimata, K. ;
Kozawa, E. ;
Futamura, N. ;
Ishiguro, N. .
BRITISH JOURNAL OF CANCER, 2011, 105 (12) :1839-1849
[4]   Measurement of high-molecular-weight hyaluronan in solid tissue using agarose gel electrophoresis [J].
Armstrong, SE ;
Bell, DR .
ANALYTICAL BIOCHEMISTRY, 2002, 308 (02) :255-264
[5]   Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival [J].
Auvinen, P ;
Tammi, R ;
Parkkinen, J ;
Tammi, M ;
Ågren, U ;
Johansson, R ;
Hirvikoski, P ;
Eskelinen, M ;
Kosma, VM .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (02) :529-536
[6]   Hyaluronan expression in differentiated thyroid carcinoma [J].
Böhm, J ;
Niskanen, L ;
Tammi, R ;
Tammi, M ;
Eskelinen, M ;
Pirinen, R ;
Hollmen, S ;
Alhava, E ;
Kosma, VM .
JOURNAL OF PATHOLOGY, 2002, 196 (02) :180-185
[7]   Pediatric malignant peripheral nerve sheath tumor: The Italian and German soft tissue sarcoma cooperative group [J].
Carli, M ;
Ferrari, A ;
Mattke, A ;
Zanetti, I ;
Casanova, M ;
Bisogno, G ;
Cecchetto, G ;
Alaggio, R ;
De Sio, L ;
Koscielniak, E ;
Sotti, G ;
Treuner, J .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8422-8430
[8]  
DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO
[9]  
2-6
[10]  
Ferner RE, 2002, CANCER RES, V62, P1573